A Clinical Study to Evaluate SM17 for Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE2

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University People's Hospital, Beijing, China
Contact: Study coordinator (Jianzhong Zhang, Dr.)
Contact: Study coordinator (Cheng Zhou)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

The Bronx, United States

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

St. Petersburg, United States

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Healthy Participants · Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE1

Anaheim, United States · Miami, United States

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE1

North Little Rock, United States · Camp Hill, United States